Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.34 |
| ▸ | AURKA | O14965 | 4/20 | 0.34 |
| ▸ | USP2 | O75604 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930743 | 0.81 | CYP1A2 (0.35) | KDRBRAFCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9930496 | 0.79 | BRAF (0.39) | KDRBRAFCYP3A4CYP2C19AURKA | |
| SCHEMBL9931389 | 0.77 | BRAF (0.46) | BRAFCYP2C9 | |
| SCHEMBL9930833 | 0.76 | BRAF (0.52) | BRAFCYP2C9 | |
| SCHEMBL9930535 | 0.75 | BRAF (0.51) | BRAFCYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL9930332 | 0.73 | BRAF (0.53) | BRAFCYP2C9 | |
| SCHEMBL9930555 | 0.73 | BRAF (0.52) | BRAFCYP2C9 | |
| SCHEMBL9930340 | 0.73 | BRAF (0.52) | BRAFCYP2C9 | |
| SCHEMBL9930459 | 0.73 | CYP1A2 (0.48) | CYP1A2CYP3A4CYP2C19CYP2D6CLK4 | |
| SCHEMBL9930607 | 0.72 | MAPT (0.56) | CYP1A2CYP3A4CYP2C19CYP2D6CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KDR 1277/4885BRAF 1/4885CYP1A2 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.